Nuveen
LMAT icon

Nuveen’s LeMaitre Vascular LMAT Stock Holding History

Nuveen’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.74M Buy
49,422
+3,844
+8% +$394K ﹤0.01% 2129
2026
Q1 		$4.98M Buy
45,578
+790
+2% +$75.3K ﹤0.01% 1884
2025
Q4 		$3.63M Sell
44,788
-862
-2% -$74.2K ﹤0.01% 2052
2025
Q3 		$3.99M Sell
45,650
-750
-2% -$67K ﹤0.01% 2012
2025
Q2 		$3.85M Sell
46,400
-8,794
-16% -$735K ﹤0.01% 2010
2025
Q1 		$4.63M Buy
55,194
+1,336
+2% +$124K ﹤0.01% 1963
2024
Q4 		$4.96M Sell
53,858
-6,355
-11% -$611K ﹤0.01% 1988
2024
Q3 		$5.59M Hold
60,213
– – ﹤0.01% 1938
2024
Q2 		$4.95M Sell
60,213
-35,044
-37% -$2.57M ﹤0.01% 1958
2024
Q1 		$6.32M Sell
95,257
-26,027
-21% -$1.61M ﹤0.01% 1855
2023
Q4 		$6.88M Buy
121,284
+2,743
+2% +$144K ﹤0.01% 1796
2023
Q3 		$6.46M Sell
118,541
-360
-0.3% -$21.3K ﹤0.01% 1739
2023
Q2 		$8M Buy
118,901
+8,608
+8% +$525K ﹤0.01% 1643
2023
Q1 		$5.68M Sell
110,293
-487
-0.4% -$23.6K ﹤0.01% 1817
2022
Q4 		$5.1M Buy
110,780
+1,506
+1% +$70.5K ﹤0.01% 1892
2022
Q3 		$5.54M Sell
109,274
-1,684
-2% -$84.2K ﹤0.01% 1837
2022
Q2 		$5.05M Buy
110,958
+328
+0.3% +$14.7K ﹤0.01% 1933
2022
Q1 		$4.88M Buy
110,630
+691
+0.6% +$30.9K ﹤0.01% 2073
2021
Q4 		$5.2M Sell
109,939
-8,039
-7% -$416K ﹤0.01% 2090
2021
Q3 		$6.26M Sell
117,978
-6,188
-5% -$349K ﹤0.01% 2089
2021
Q2 		$7.58M Sell
124,166
-578
-0.5% -$30.7K ﹤0.01% 2022
2021
Q1 		$6.08M Sell
124,744
-1,551
-1% -$72.7K ﹤0.01% 2075
2020
Q4 		$5.12M Sell
126,295
-318
-0.3% -$11.4K ﹤0.01% 2062
2020
Q3 		$4.12M Buy
126,613
+407
+0.3% +$12.2K ﹤0.01% 2023
2020
Q2 		$3.33M Sell
126,206
-12,765
-9% -$334K ﹤0.01% 2110
2020
Q1 		$3.46M Buy
138,971
+24,679
+22% +$762K ﹤0.01% 1906
2019
Q4 		$4.11M Sell
114,292
-6,449
-5% -$223K ﹤0.01% 2091
2019
Q3 		$4.13M Buy
120,741
+27,370
+29% +$875K ﹤0.01% 2061
2019
Q2 		$2.61M Buy
+93,371
New +$2.59M ﹤0.01% 2301

Other funds holding LMAT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen's LMAT Position: Q2 2026 in Review

Nuveen increased its LeMaitre Vascular (LMAT) stake by 8.4% in Q2 2026, buying an estimated $394K and bringing the position to 49,422 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2129.

Nuveen first reported a position in LMAT in Q2 2019 and has held it in 29 quarters since. The position peaked at $8M in Q2 2023. 326 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.

  • Nuveen held 49,422 shares of LeMaitre Vascular worth $4.74M as of Q2 2026.
  • Nuveen bought 3,844 LeMaitre Vascular shares in Q2 2026, an estimated $394K.
  • LeMaitre Vascular made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2129 holding.
  • Nuveen first reported a position in LeMaitre Vascular in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's LeMaitre Vascular position peaked at $8M in Q2 2023.
  • 326 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.